Laryxin Honey

Chlorhexidine dihydrochloride and lidocaine hydrochloride monohydrate, the active ingredients in Laryxin Honey, are an antiseptic and a local anesthetic presented as an oromucosal solution for topical use in the mouth. They are employed to reduce microbial load and provide temporary pain relief in conditions such as oral mucositis, sore throat and oral ulcerations.

GNH USA supplies Laryxin Honey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Laryxin Honey combines chlorhexidine and lidocaine to address infections and pain in the oral mucosa, making it useful in several common conditions. - Oral mucositis: the antiseptic reduces bacterial colonisation while the anaesthetic provides temporary numbness, helping patients tolerate chemotherapy‑induced lesions and maintain nutrition. - Sore throat: chlorhexidine lowers throat microbial load and lidocaine offers rapid local numbing, relieving irritation and facilitating swallowing. - Oral ulcer pain: the formulation numbs ulcerated areas and inhibits infection, improving comfort during eating and speaking.

Laryxin Honey may cause local and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Altered taste sensation: temporary metallic or bitter taste. - Oral irritation or burning: mild discomfort at application site. - Numbness of the mouth or throat: transient loss of sensation. - Mild headache: occasional after extensive use.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Severe mucosal ulceration: unexpected worsening of lesions. - Persistent numbness: prolonged sensory loss beyond expected duration. - Systemic toxicity: signs such as dizziness or cardiac arrhythmia (rare with excessive absorption).

When using Laryxin Honey, observe the following precautions to minimise risks and ensure optimal benefit. - Allergy assessment: verify no known hypersensitivity to chlorhexidine, lidocaine or related compounds. - Application site: avoid use on extensive open wounds or severely damaged mucosa. - Duration of use: limit treatment to the shortest period required, typically not exceeding 7‑10 days without medical review. - Concomitant anesthetics: do not combine with other topical anesthetics to prevent additive toxicity. - Systemic absorption: monitor patients with large oral lesions for signs of systemic lidocaine exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Laryxin Honey can interact with certain medicines or products; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Other chlorhexidine‑containing products: concurrent use may increase mucosal irritation. - Additional topical anesthetics: combined use can lead to excessive local anaesthetic effect and systemic toxicity. - Systemic antihistamines: may mask early signs of an allergic reaction to the product.

Moderate Interactions (Monitor Closely): - Alcohol‑based mouthwashes: may enhance burning sensation and mucosal irritation. - Anticoagulant therapy (e.g., warfarin): extensive oral lesions plus antiseptic use could modestly increase bleeding risk. - Proton pump inhibitors: may alter oral mucosal pH, potentially affecting chlorhexidine activity.